A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer

Journal of Urology

Volumn 165, Issue 5 I, 2001, Pages 1549-1553

  Mitchell, I D C ^a   Croal, B L ^a   Dickie, A ^a   Cohen, N P ^a   Ross, I ^a  

^a NHS GRAMPIAN   (United Kingdom)

Author keywords

Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; COMPLEX FORMATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 0035043426     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)66346-x     Document Type: Article

References (18)

1. Purification of a human prostate-specific antigen
2. Serum prostate-specific antigen in a community based population of healthy men. Establishment of age specifc ranges
3. Prostate specific antigen density (PSAD). Role in patient evaluation and management
4. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
5. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves the clinical sensitivity for cancer
6. Determination of antigen-alpha 1-antichymotrypsin complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA
7. A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha 1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not those with benign prostate hyperplasia
8. Issues in the assessment of PSA immunoassays
9. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease
10. Determination of the "reflex range" and appropriate cut-off points for percent-free PSA in 413 men referred for prostatic evaluation using the AxSYN system
11. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
12. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10 ng/ml
13. Measurement of complexed PSA improves specificity for early detection of prostate cancer
14. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
15. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
16. The stability of free and bound prostate-specific antigen
17. Making the most out of six systematic sextant biopsies
18. Alpha 1-antichymotrypsin production in PSA producing cells is common in prostate cancer but rare in benign prostatic hyperplasia